42 results on '"Le Calloch, R."'
Search Results
2. P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY
- Author
-
Hulin, C., primary, Macro, M., additional, Perrot, A., additional, Royer, B., additional, Caillot, D., additional, Belhadj, K., additional, Frenzel, L., additional, Benramdane, R., additional, Demarquette, H., additional, Bareau, B., additional, Darre, S., additional, Calmettes, C., additional, Le Calloch, R., additional, Bouketouche, M., additional, Laribi, K., additional, Texier, N., additional, Willaime, M., additional, Deal, C., additional, Moreau, P., additional, and Decaux, O., additional
- Published
- 2022
- Full Text
- View/download PDF
3. P672: REAL-LIFE EFFICACY AND SAFETY OF VENETOCLAX MONOTHERAPY IN RELAPSED/ REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA - INTERIM ANALYSIS OF MULTICENTRIC STUDY VERONE
- Author
-
Ysebaert, L., primary, Troussard, X., additional, Levy, V., additional, Le Calloch, R., additional, Guieze, R., additional, Leprêtre, S., additional, Michallet, A.-S., additional, Leblond, V., additional, Feugier, P., additional, Ramier, J., additional, and Delmer, A., additional
- Published
- 2022
- Full Text
- View/download PDF
4. IMPLICATION OF CYCLOSPORINE IN THE DEVELOPMENT OF REVERSIBLE POSTERIOR ENCEPHALOPATHY SYNDROME IN THREE PATIENTS WITH ALLOGENIC BONE MARROW TRANSPLANTS: IS MRI APPARENT DIFFUSION COEFFICIENT OF PROGNOSTIC AND THERAPEUTIC VALUE?: PH-AB081
- Author
-
Le Calloch, R., Guillerm, G., Ianotto, J.-C., Bailly, P., Tissot, V., Imbeault, B., Tempescul, A., Dalbies, F., Eveillard, J.-R., Berthou, C., and Timsit, S.
- Published
- 2014
5. Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients
- Author
-
Ianotto, J-C, Tempescul, A, Yan, X, Delepine, P, Le Calloch, R, Hardy, E, Eveillard, J-R, Mugnier, N, Berthou, C, and Guillerm, G
- Published
- 2012
- Full Text
- View/download PDF
6. La leucoencéphalopathie multifocale progressive (LEMP) : une pathologie émergente en hématologie ?
- Author
-
Couret, D., primary, Le Calloch, R., additional, Eveillard, J., additional, Hutin, P., additional, Guillerm, G., additional, and Talarmin, J., additional
- Published
- 2018
- Full Text
- View/download PDF
7. Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
- Author
-
Gaye, E., primary, Le Bot, A., additional, Talarmin, J.P., additional, Le Calloch, R., additional, Belaz, S., additional, Dupont, M., additional, and Tattevin, P., additional
- Published
- 2018
- Full Text
- View/download PDF
8. Responses and Survival under Pegylated Interferon α2a Treatment for Patients with Post-MPN Acute Myeloid Leukemia and Acute Panmyelosis with Myelofibrosis
- Author
-
Mélanie Mercier, Luque Paz D, Christian Berthou, G. Guillerm, Douet-Guilbert N, Ugo, Le Calloch R, Dagorne A, Isabelle Quintin-Roué, Boyer-Perrard F, Aurélie Chauveau, and Ianotto Jc
- Subjects
Oncology ,medicine.medical_specialty ,Acute leukemia ,business.industry ,Myeloid leukemia ,medicine.disease ,Open access publishing ,Pegylated interferon ,Internal medicine ,medicine ,Acute panmyelosis with myelofibrosis ,Myelofibrosis ,business ,medicine.drug - Published
- 2016
- Full Text
- View/download PDF
9. La leuco-encéphalopathie multifocale progressive non liée au VIH, émergence d’une complication redoutable à l’ère des biothérapies ?
- Author
-
Couret, D., primary, Le Calloch, R., additional, Talarmin, J.P., additional, Eveillard, J.R., additional, and Hutin, P., additional
- Published
- 2017
- Full Text
- View/download PDF
10. Gammapathie monoclonale de signification clinique cutanée avec maladie neutrophilique cutanée et extra-cutanée
- Author
-
Mahe, K., primary, Hutin, P., additional, Plantin, P., additional, Talarmin, J.P., additional, and Le Calloch, R., additional
- Published
- 2017
- Full Text
- View/download PDF
11. Thrombocytémie essentielle avec prurit aquagénique : une entité plus agressive au diagnostic et une forte morbidité au cours du suivi
- Author
-
Le Gall-Ianotto, C., primary, Le Calloch, R., additional, Mollard, L.-M., additional, Misery, L., additional, and Ianotto, J.-C., additional
- Published
- 2016
- Full Text
- View/download PDF
12. Hemorrhagic Cystitis due to BK Reactivation in a Young Female Treated for Hodgkin-Disease
- Author
-
Le Calloch, R., Ianotto, J. C., Berthou, C., and Tempescul, A.
- Subjects
Article Subject ,viruses ,virus diseases - Abstract
Hodgkin's lymphoma is a disease with a high rate of curability under classic chemo-radiotherapy regimes. Complications due to chemotherapy could include viral reactivation due to chronic lymphopenia. BK virus (BKV) is a polyoma virus belonging to the Papovaviridae family with antibody seroprevalences in healthy populations varying from 60% to 80%. Initial infections are asymptomatic usually occur in early childhood, after which the viruses remain latent in the kidneys or urothelium. Reactivation of BKV occurs in individuals with severe immunosuppression during HIV infections, transplantation or, exceptionally, after classical chemotherapy. BKV incidence is approximately 0% to 5% in immunocompetent individuals. Reactivation is associated with nephropathy and haemorrhagic cystitis. Herein, we present a case of a haemorrhagic cystitis due to BKV reactivation in a patient with Hodgkin's disease treated with chemotherapy.
- Published
- 2011
- Full Text
- View/download PDF
13. Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR).
- Author
-
Fornecker, L., Delwail, V., Thieblemont, C., Ghesquieres, H., Bouabdallah, K., Tilly, H., Le Calloch, R., Morschhauser, F., Costello, R., Slama, B., Gyan, E., Chauchet, A., Ngirabacu, M., Durot, E., Choquet, S., Capdupuy, C., Le Goff, M., Voillat, L., Snauwaert, S., and Amorim, S.
- Subjects
NON-Hodgkin's lymphoma ,IFOSFAMIDE ,RITUXIMAB ,DIFFUSE large B-cell lymphomas - Abstract
R/R disease was defined as follows: (1) autologous stem-cell transplantation (ASCT) eligible patients who failed to achieve a CR after at least one salvage therapy, (2) patients in first relapse after ASCT or (3) patients not eligible for ASCT who failed to achieve a CR after at least one prior treatment. Results from a phase II LYSA study (PIVeR) B Introduction: b The prognosis of patients with relapsed/refractory aggressive non-hodgkin lymphoma (R/R aNHL) remains poor with conventional immunochemotherapies. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
14. Fungal arthritis of the hip in patient with aplastic anaemia
- Author
-
Le Calloch, R., primary, Ianotto, J.-C., additional, Guillerm, G., additional, and Tonnelier, J. M., additional
- Published
- 2013
- Full Text
- View/download PDF
15. Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients
- Author
-
Ianotto, J-C, primary, Tempescul, A, additional, Yan, X, additional, Delepine, P, additional, Le Calloch, R, additional, Hardy, E, additional, Eveillard, J-R, additional, Mugnier, N, additional, Berthou, C, additional, and Guillerm, G, additional
- Published
- 2011
- Full Text
- View/download PDF
16. OUTCOME AFTER RIC ALLO-STEM CELL TRANSPLANTATION FOR PATIENTS WITH MANTLE CELL LYMPHOMA WHO RELAPSED AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION, A RETROSPECTIVE STUDY OF THE SFGM-TC GROUP
- Author
-
Tessoulin, B., Cartron, G., Blaise, D., Tournilhac, O., Ibrahim Yakoub-Agha, Delwail, V., Milpied, N., Choquet, S., Gressin, R., Ifrah, N., Le Calloch, R., Mohty, M., Tilly, H., Socie, G., Cornillon, J., Deconinck, E., and Le Gouill, S.
17. Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies.
- Author
-
Soulard M, Galicier L, Mahlaoui N, Fieschi C, Deshayes S, Gobert D, Gourguechon C, Henique H, Humbert S, Lacout C, Le Calloch R, Michel M, Piel-Julian ML, Viallard JF, Lescoat A, Godeau B, and Perlat A
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Aged, Treatment Outcome, Retrospective Studies, Thrombopoietin therapeutic use, Thrombopoietin adverse effects, Recombinant Fusion Proteins therapeutic use, Young Adult, Aged, 80 and over, Receptors, Fc therapeutic use, Benzoates, Hydrazines, Pyrazoles, Receptors, Thrombopoietin agonists, Purpura, Thrombocytopenic, Idiopathic drug therapy
- Abstract
Abstract: Predominantly antibody deficiencies have an estimated prevalence of >1 in 25 000. Their classical phenotype entails the association of autoimmune manifestations with increased susceptibility to infections. Up to 8% of these patients ultimately develop immune thrombocytopenic purpura (ITP). Reducing the risk for infections and considering nonimmunosuppressive treatments, such as thrombopoietin receptor agonists (TPO-RAs), are important considerations for these patients. This nationwide retrospective case series assessed the outcomes and safety of TPO-RAs as treatment for ITP in adults diagnosed with predominantly antibody deficiencies. Response and complete response to treatment were defined as platelet count reaching 30 × 109/L and 100 × 109/L, respectively. We analyzed data from 28 patients. The median follow-up time after introduction of the first TPO-RAs was 33 months (range, 2 weeks to 10.6 years). After 6 weeks of follow-up, response was achieved in 24 of the 28 patients (85.7%), and among those, 21 patients (75%) displayed a complete response. At the last available follow-up visit, only 7 patients (25%) needed second-line therapies for ITP, and among those, only 5 patients (17.9%) received immunosuppressants. Only 3 patients (10.7%) reported laboratory-confirmed hepatobiliary adverse events of light or mild severity and 3 patients (10.7%) reported thrombotic events. In conclusion, TPO-RAs seemed to be an effective and safe option of treatment in these case series. Our results suggest that eltrombopag or romiplostim should be considered as second-line therapy for ITP related to predominantly antibody deficiencies., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. [Nurturing and growing a community of department heads: Act 2 in haematology].
- Author
-
Houot R, Calmettes C, Park S, Pascal L, Peffault de Latour R, Pigneux A, Quinquenel A, Raffoux E, Thieblemont C, Touati M, Trebouet A, Vaida I, Wémeau M, Bastie JN, Bay JO, Cluzeau T, Cornillon J, Damaj G, Deconinck E, Feugier P, Fornecker LM, Gay J, Hermine O, Hospital MA, Hunault M, Jaccard A, Jardin F, Le Calloch R, Legros L, Leleu X, Lemonnier F, Malfuson JV, Morel P, Ochmann M, Orsini-Piocelle F, and Gyan E
- Subjects
- Humans, France, Peer Group, Hematology organization & administration, Hospital Departments organization & administration
- Abstract
In response to the French hospital system crisis and the challenges faced by the heads of departments, we have undertaken an initiative to create a community of heads of haematology departments willing to assist each other. Our inaugural seminar, held in January 2023, established the foundational "core" group of heads of department. Throughout 2023, this emerging community has prospered, offering sustained support to peers. In January 2024, we broadened our community to include other heads of departments, following a second seminar gathering 36 participants. During this event, we took the time to exchange thoughts and reflect on our missions. Building on the experience of guest speakers and employing methods of co-development and co-construction in plenary sessions, small-group workshops, and social gathering, we were able to discover and experience the collective intelligence, creativity, strength, and support stemming from such a group. This peer community of heads of departments stands as a powerful tool for management support, whereby personal experiences nourish and enrich the experience of others. We hope that our initiative will inspire heads of departments from other specialties so that, together, we can better work towards our missions as heads of departments and collaborate on rebuilding the hospital "from the bottom up"., (Copyright © 2024 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
- Author
-
Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, Roussel M, Montes L, Cherel B, Chalopin T, Slama B, Chretien ML, Laribi K, Dingremont C, Roul C, Mariette C, Rigaudeau S, Calmettes C, Dib M, Tiab M, Vincent L, Delaunay J, Santagostino A, Macro M, Bourgeois E, Orsini-Piocelle F, Gay J, Bareau B, Bigot N, Vergez F, Lebreton P, Tabrizi R, Waultier-Rascalou A, Frenzel L, Le Calloch R, Chalayer E, Braun T, Lachenal F, Corm S, Kennel C, Belkhir R, Bladé JS, Joly B, Richez-Olivier V, Gardeney H, Demarquette H, Robu-Cretu D, Garderet L, Newinger-Porte M, Kasmi A, Royer B, Decaux O, Arnulf B, Belhadj K, Touzeau C, Mohty M, Manier S, Moreau P, Avet-Loiseau H, Corre J, and Facon T
- Subjects
- Humans, Aged, Male, Female, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Neoplasm, Residual, Treatment Outcome, Multiple Myeloma drug therapy, Multiple Myeloma pathology, Bortezomib administration & dosage, Bortezomib therapeutic use, Lenalidomide administration & dosage, Lenalidomide therapeutic use, Dexamethasone administration & dosage, Dexamethasone therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use
- Abstract
CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of care (SOC). To improve current SOC, we evaluated the added value of weekly bortezomib (V) to isatuximab plus lenalidomide and dexamethasone (IsaRd versus Isa-VRd). This Intergroupe Francophone of Myeloma phase 3 study randomized 270 patients with NDMM that were TI, aged 65-79 years, to IsaRd versus Isa-VRd arms. The primary endpoint was a minimal residual disease (MRD) negativity rate at 10
-5 by next-generation sequencing at 18 months from randomization. Key secondary endpoints included response rates, MRD assessment rates, survival and safety. The 18-month MRD negativity rates at 10-5 were reported in 35 patients (26%, 95% confidence interval (CI) 19-34) in IsaRd versus 71 (53%, 95% CI 44-61) in Isa-VRd (odds ratio for MRD negativity 3.16, 95% CI 1.89-5.28, P < 0.0001). The MRD benefit was consistent across subgroups at 10-5 and 10-6 , and was already observed at month 12. The proportion of patients with complete response or better at 18 months was higher with Isa-VRd (58% versus 33%; P < 0.0001), as was the proportion of MRD negativity and complete response or better (37% versus 17%; P = 0.0003). At a median follow-up of 23.5 months, no difference was observed for survival times (immature data). The addition of weekly bortezomib did not significantly affect the relative dose intensity of IsaRd. Isa-VRd significantly increased MRD endpoints, including the 18-month negativity rate at 10-5 , the primary endpoint, compared with IsaRd. This study proposes Isa-VRd as a new SOC for patients with NDMM that are TI. ClinicalTrials.gov identifier: NCT04751877 ., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
20. Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
- Author
-
Laribi K, Poulain S, Willems L, Merabet F, Herbaux C, Roos-Weil D, Laribi de Materre I, Roussel X, Nudel M, Tricot S, Dupuis J, Le Calloch R, Bareau B, and Leblond V
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Aged, 80 and over, France, Follow-Up Studies, Treatment Outcome, Bendamustine Hydrochloride administration & dosage, Bendamustine Hydrochloride therapeutic use, Waldenstrom Macroglobulinemia drug therapy, Waldenstrom Macroglobulinemia mortality, Rituximab administration & dosage, Rituximab therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use
- Abstract
The bendamustine-rituximab (BR) schedule is an efficient first-line therapy in Waldenström macroglobulinaemia (WM). A previous analysis of 69 patients who received this treatment confirmed a high response rate and good progression-free (PFS) and overall survival (OS). With a median follow-up of 76.1 months (95% confidence interval [CI] 69.9-80.6), 5-year outcome is still excellent at 66.63% (95% CI 56.09-79.17) for PFS and 80.01% (95% CI 70.82-90.41) for OS. The rate of secondary cancers is 17.66% (IQR 7.99-27.64) at 66 months. Relapsed patients who received ibrutinib as second-line clearly benefited from this schedule. This confirms current recommendations suggesting BR long-term efficacy as first-line option in WM., (© 2024 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
21. Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.
- Author
-
Laribi K, Leleu X, Texier N, Germain R, Touzeau C, Hammoud M, Payssot A, Schulmann S, Le Calloch R, Trebouet A, Chaoui D, David S, Benbrahim O, Benramdane R, Charvet-Rumpler A, Jadeau C, Rouanet E, Decaux O, and Perrot A
- Abstract
The real-life retrospective observational study CARMYN aimed at investigating the long-term efficacy and safety of carfilzomib in combination with dexamethasone and lenalidomide (KRd, 159 patients). These patients (62% in first and 38% in second relapse, median age 62 yo) were treated between 02/2014 and 02/2017. Most had been pre-exposed to bortezomib (98.2%) and to an IMID (75.4%). At the time of collection, 90% had permanently discontinued carfilzomib. Data collection was conducted from January to July 2021 in 27 participating sites, after a median of 39 months follow-up. For patients treated with KRd, an overall response rate of 78.4% translated in a median progression free survival (PFS) of 24.0 months (95% CI 18.8-27.6) and a median overall survival (OS) of 51.1 months (95% CI 41.3-not reached). Results were poorer but difficult to interpret in the small cohort of Kd recipients. The study is one of the longest real-life studies of carfilzomib treatment in patients in first or second relapse. CARMYN confirmed the real-life long-term efficacy of carfilzomib in combination with lenalidomide and dexamethasone with results similar to those of clinical trials. The KRd regimen is thus an option to consider for late relapses in the current context of MM management., Competing Interests: KL received honoraria from AbbVie, AstraZeneca, Beigene, Iqone, Janssen, Novartis and Takeda. XL is a consultant and received honoraria from Amgen, Merck, BMS, GSK, Janssen, Oncopeptide, Takeda, Roche, Novartis, AbbVie, Sanofi, Gilead, Pfizer, Harpoon Therapeutic, Regeneron and Iteos. CT received adboards and honoraria from AMGEN. RLC received honoraria from Abbvie, Gilead, Takeda and Janssen.DC received honoraria from Roche. AP received honoraria from Abbvie, Amgen, BMS, Janssen, Pfizer, Sanofi & Takeda. The other authors declare no financial interests., (© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
22. Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma.
- Author
-
Vély A, Couturier MA, Delepine P, Le Calloch R, Ertault M, Gastinne T, Plichon C, Lebreton A, Lester MA, Larhantec G, Cormier N, Fouquet S, Houot R, Tanguy-Schmidt A, Hunault-Berger M, and Orvain C
- Subjects
- Humans, Etoposide adverse effects, Retrospective Studies, Transplantation, Autologous, Cytarabine adverse effects, Carmustine adverse effects, Melphalan adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Hodgkin Disease diagnosis, Hodgkin Disease therapy, Hematopoietic Stem Cell Transplantation adverse effects, Mucositis chemically induced
- Abstract
The combination of carmustine, etoposide, cytarabine, and melphalan (BEAM) followed by autologous stem cell transplantation (ASCT) is a commonly used intensification regimen for patients with Hodgkin lymphoma. As etoposide and cytarabine dosing are not defined, we conducted a retrospective, multicenter study, to compare efficacy and toxicity in 130 patients with Hodgkin lymphoma receiving etoposide and cytarabine at either 200 mg/m
2 /d ( n = 50), 400 mg/m2 /d ( n = 35), or etoposide 200 mg/m2 /d and cytarabine 400 mg/m2 /d ( n = 45). Progression-free survival and overall survival were not associated with the intensity of conditioning. Increased conditioning intensity was associated with longer duration of thrombocytopenia, a higher number of transfused RBC and platelet units and a higher frequency of mucositis, but serious adverse events or infectious complications were not increased. The intensity of BEAM regimen was not associated with survival but with the rate of cytopenia and mucositis advocating for the use of lower dosing in frail patients.- Published
- 2023
- Full Text
- View/download PDF
23. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
- Author
-
Aubrais R, Bouabdallah K, Chartier L, Herbaux C, Banos A, Brice P, Sibon D, Schiano JM, Cluzeau T, Laribi K, Le Calloch R, Bellal M, Delapierre B, Daguindau N, Amorim S, Agbetiafa K, Chauchet A, Besson C, Durot E, Bonnet C, Fouillet L, Bijou F, Tournilhac O, Gaulard P, Parrens MC, and Damaj G
- Subjects
- Humans, Brentuximab Vedotin therapeutic use, Bendamustine Hydrochloride therapeutic use, Retrospective Studies, Salvage Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols adverse effects, Neoplasm Recurrence, Local drug therapy, Chronic Disease, Lymphoma, T-Cell, Peripheral drug therapy, Hodgkin Disease drug therapy
- Abstract
Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination. This multicenter and retrospective study aimed to evaluate the efficacy and safety of the combination of BBv in patients with noncutaneous R/R PTCL among 21 LYSA centers in France and Belgium. The primary objective was the overall response rate. A total of 82 patients with R/R PTCL were included. The best overall response rate (ORR) was 68%, with 49% of patients in complete response (CR). In multivariable analysis, only the disease status after the last regimen (relapse vs refractory) was associated with the response with an ORR of 83% vs 57%. Median duration of response was 15.4 months for patients in CR. With a median follow-up of 22 months, the median progression free survival (PFS) and overall survival (OS) were 8.3 and 26.3 months respectively. Moreover, patients in CR, who underwent an allogeneic transplant, had a better outcome than patients who did not with a median PFS and OS of 19.3 vs 4.8 months and not reached vs 12.4 months, respectively. Fifty-nine percent of patients experienced grade 3/4 adverse events that were mainly hematologic. BBv is highly active in patients with R/R PTCL and should be considered as a one of the best options of immunochemotherapy salvage combination in this setting and particularly as a bridge to allogeneic transplant for eligible patients., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
- Author
-
Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, Petillon MO, Allangba O, Agape P, Arnautou P, Belkhir R, Cailleres S, Chaoui D, Chrétien ML, Decaux O, Schulmann S, Frenzel L, Gastaud L, Huart A, Hulin C, Karlin L, Laribi K, Le Calloch R, Lenain P, Macro M, Manier S, Montes L, Moreau S, Moreau P, Morel V, Norwood J, Piocelle FO, Perrot A, Pica GM, Rey P, Schmitt A, Stoppa AM, Tiab M, Touzeau C, Vidal V, Vignon M, Vincent L, Van De Wyngaert Z, Zarnitsky C, Kerbouche N, Paka P, Leleu X, Arnulf B, Avet-Loiseau H, and Du Myélome IIF
- Subjects
- Adult, Humans, Aged, Treatment Outcome, Retrospective Studies, France, Multiple Myeloma drug therapy
- Abstract
Belantamab mafodotin (BM) is an anti-BCMA antibody-drug conjugate (GSK2857916) that represents an alternative option in multiple myeloma. We sought to assess the efficacy and safety of BM in a real-world setting in patients who benefited from an early access program. We conducted an observational, retrospective, multicenter study. Eligibility criteria were treatment of relapsed or refractory multiple myeloma (RRMM) in monotherapy in adult patients who have received at least three lines of therapy previously, including at least one immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody, and whose disease progressed during the last treatment period. The primary endpoint of the study is to assess the overall survival (OS). Between November 2019 and December 2020, 106 patients were treated with BM; 97 were eligible for the efficacy evaluation and 104 for safety. The median age was 66 (range, 37-82) years. High-risk cytogenetics were identified in 40.9% of patients. Fifty-five (56.7%) patients were triple-class refractory and 11 (11.3%) were penta-class refractory. The median number of prior lines of treatment was five (range, 3-12). The median number of BM cycles administered was three (range, 1-22). The overall response rate at best response was 38.1% (37/97). The median OS was 9.3 months (95% confidence interval [CI]: 5.9-15.3), and median progression-free survival was 3.5 months (95% CI: 1.9-4.7). The median duration of response was 9 months (range, 4.65-10.4). Treatment was delayed for 55 (52.9%) patients including 36.5% for treatment-related toxicity. Ophthalmic adverse events, mainly grade ≤2, were the most common toxicity (48%). The occurrence of keratopathy was 37.5%. Overall, our data are concordant with the results from DREAMM-2 in terms of efficacy and safety on a non-biased population.
- Published
- 2023
- Full Text
- View/download PDF
25. Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm.
- Author
-
Le Calloch R, Arnaud B, Le Clech L, Hutin P, Salmon F, Garnache Ottou F, Ianotto JC, and Laribi K
- Subjects
- Aged, 80 and over, Azacitidine therapeutic use, Bridged Bicyclo Compounds, Heterocyclic, Dendritic Cells, Female, Humans, Sulfonamides, Myeloproliferative Disorders, Skin Neoplasms drug therapy
- Published
- 2022
- Full Text
- View/download PDF
26. Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy.
- Author
-
Laribi K, Baugier de Materre A, Ghez D, Dartigeas C, Tomowiak C, Mahé B, Micol JB, Merabet F, Leprêtre S, Herbaux C, Ysebaert L, Le Calloch R, Willems L, Voldoire M, Roos-Weil D, Bravetti C, Touileb Y, Davi F, Nguyen-Khac F, Maloum K, and Béné MC
- Published
- 2022
- Full Text
- View/download PDF
27. Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma.
- Author
-
Rebière V, Maajem M, Le Calloch R, Raj L, Le Bris AS, Malou M, Salmon F, Quintin-Roué I, Tempescul A, Bourhis D, Samaison L, Saad H, Salaun PY, Berthou C, Ianotto JC, Abgral R, and Eveillard JR
- Abstract
Currently, prognostic models in diffuse large B-cell lymphoma (DLBCL) fail to closely reflect patients' biological, clinical, and survival heterogeneity. We, therefore, assessed the impact of clinical, biological, immunohistochemical (IHC), baseline (0), and interim (after 2 and 4 treatment cycles) PET (PET0, PET2, and PET4) data not yet included in any scoring system on DLBCL outcome. The analysis was conducted on 89 previously untreated adult patients of the Finistere Observatory Cohort (O.Ly.Fin) with documented DLBCL, recruited between January 2010 and December 2017, with progression-free survival (PFS) and overall survival (OS) as primary and secondary endpoints, respectively. Seventy-eight patients were treated with rituximab, cyclophosphamide, hydroxyadriamycin, vincristine, and prednisone (R-CHOP), while 11 received R-dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and hydroxyadriamycin (EPOCH). Patients were followed up until June 20, 2020. On multivariate analysis, Ki67 ≥ 70% on IHC (K), bulky presentation ≥7.5 cm (B), meningeal lymphomatosis (M), and PET0-PET4 ΔSUVmax <71% (P4) were identified as strong independent predictors of PFS, and all variables but bulky disease also strongly and independently predicted OS. Using these 4 parameters, we designed a scoring model named KBMP4 stratifying patients into low- (0 parameter), intermediate- (1 or 2), and high-risk (≥3) subgroups by the Kaplan-Meier analysis. At a median follow-up of 43 months, PFS and OS were both 100% in the low-risk subgroup, 71.4 and 90.5%, respectively, in the intermediate-risk subgroup, and 0 and 55.5%, respectively, in the high-risk subgroup. Use of the KBMP4 model in clinical practice may improve accuracy in prognostic prediction and treatment decisions in de novo DLBCL patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Rebière, Maajem, Le Calloch, Raj, Le Bris, Malou, Salmon, Quintin-Roué, Tempescul, Bourhis, Samaison, Saad, Salaun, Berthou, Ianotto, Abgral and Eveillard.)
- Published
- 2022
- Full Text
- View/download PDF
28. Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders.
- Author
-
Herbreteau L, Le Calloch R, Arnaud B, Cassou N, Rizcallah MJ, Hutin P, and Le Clech L
- Subjects
- Aged, Anemia, Hemolytic, Autoimmune immunology, Cryoglobulins immunology, Humans, Lymphoproliferative Disorders immunology, Male, Anemia, Hemolytic, Autoimmune complications, Anemia, Hemolytic, Autoimmune drug therapy, Antibodies, Monoclonal, Humanized therapeutic use, Complement Inactivating Agents therapeutic use, Lymphoproliferative Disorders complications
- Published
- 2021
- Full Text
- View/download PDF
29. Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
- Author
-
Oberic L, Peyrade F, Puyade M, Bonnet C, Dartigues-Cuillères P, Fabiani B, Ruminy P, Maisonneuve H, Abraham J, Thieblemont C, Feugier P, Salles G, Bijou F, Pica GM, Damaj G, Haioun C, Casasnovas RO, Farhat H, Le Calloch R, Waultier-Rascalou A, Malak S, Paget J, Gat E, Tilly H, and Jardin F
- Subjects
- Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols pharmacology, Humans, Injections, Subcutaneous, Lenalidomide pharmacology, Male, Prognosis, Rituximab pharmacology, Transcription Factor CHOP pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lenalidomide therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy, Rituximab therapeutic use, Transcription Factor CHOP therapeutic use
- Abstract
Purpose: The prognosis of elderly patients with diffuse large B-cell lymphoma (DLBCL) is worse than that of young patients. An attenuated dose of chemotherapy-cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-miniCHOP)-is a good compromise between efficacy and safety in very elderly patients. In combination with R-CHOP (R2-CHOP), lenalidomide has an acceptable level of toxicity and may mitigate the negative prognosis of the non-germinal center B-cell-like phenotype. The Lymphoma Study association conducted a multicentric, phase III, open-label, randomized trial to compare R-miniCHOP and R2-miniCHOP., Patients and Methods: Patients of age 80 years or older with untreated DLBCL were randomly assigned into the R-miniCHOP21 group or the R2-miniCHOP21 group for six cycles and stratified according to CD10 expression and age. The first cycle of rituximab was delivered by IV on D1 after a prephase and then delivered subcutaneously on D1 of cycles 2-6. Lenalidomide was delivered at a dose of 10 mg once daily on D1-D14 of each cycle. The primary end point was overall survival (OS)., Results: A total of 249 patients with new DLBCL were randomly assigned (127 R-miniCHOP and 122 R2-miniCHOP). The median age was 83 years (range, 80-96), and 55% of the patients were classified as non-GCB. The delivered dose for each R-miniCHOP compound was similar in both arms. Over a median follow-up of 25.1 months, the intention-to-treat analysis revealed that R2-miniCHOP did not improve OS (2-year OS 66% in R-miniCHOP and 65.7% in R2-miniCHOP arm, P = .98) in the overall population or in the non-GCB population. Grade 3-4 adverse events occurred in 53% of patients with R-miniCHOP and in 81% of patients with R2-miniCHOP., Conclusion: The addition of lenalidomide to R-miniCHOP does not improve OS. Rituximab delivered subcutaneously was safe in this population., Competing Interests: Lucie ObericHonoraria: Roche, Janssen-CilagConsulting or Advisory Role: Roche, TakedaTravel, Accommodations, Expenses: Roche, Janssen-Cilag Frederic PeyradeHonoraria: MSD Oncology Mathieu PuyadeTravel, Accommodations, Expenses: Sanofi Pasteur Christophe BonnetConsulting or Advisory Role: Roche Julie AbrahamHonoraria: Sanofi Pasteur, Gilead Sciences, RocheTravel, Accommodations, Expenses: Janssen-Cilag, Abbvie Catherine ThieblemontHonoraria: Celgene, Abbvie, Bayer, Janssen, Roche, Incyte, Novartis, Gilead SciencesResearch Funding: RocheTravel, Accommodations, Expenses: Roche, Janssen-Cilag, Kite/Gilead, Novartis Pierre FeugierHonoraria: Roche/Genentech, Janssen, Gilead Sciences, Amgen, AbbvieConsulting or Advisory Role: Roche/Genentech, Janssen, Abbvie, Gilead Sciences, Amgen, AstraZenecaSpeakers' Bureau: Roche/Genentech, Abbvie, Amgen, Janssen, Gilead SciencesResearch Funding: Roche/Genentech, Gilead Sciences, Janssen, Abbvie, AmgenTravel, Accommodations, Expenses: Amgen, Gilead Sciences, Janssen, Roche/Genentech, Abbvie Gilles SallesHonoraria: Roche/Genentech, Janssen, Celgene, Gilead Sciences, Novartis, Abbvie, MorphoSysConsulting or Advisory Role: Roche/Genentech, Gilead Sciences, Janssen, Celgene, Novartis, Morphosys, Epizyme, Alimera Sciences, Genmab, Debiopharm Group, Velosbio Gandhi DamajConsulting or Advisory Role: Roche/Genentech, Takeda, iqoneResearch Funding: TakedaTravel, Accommodations, Expenses: Pfizee, Roche/Genentech, Abbvie Corinne HaiounHonoraria: Roche France, Janssen-Cilag, Gilead Sciences, Miltenyi Biotec, Amgen, Takeda, Celgene, Novartis,, Servier/PfizerConsulting or Advisory Role: Roche, Celgene, Janssen-Cilag, Gilead Sciences, Takeda, Miltenyi BiotecTravel, Accommodations, Expenses: Roche, Celgene, Amgen René-Olivier CasasnovasHonoraria: Roche/Genentech, Takeda, Gilead Sciences, Bristol-Myers Squibb, Merck, Abbvie, Celgene, JanssenConsulting or Advisory Role: Roche/Genentech, Takeda, Gilead Sciences, Bristol-Myers Squibb, Merck, Abbvie, Celgene, JanssenResearch Funding: Roche/Genentech, Gilead Sciences, TakedaTravel, Accommodations, Expenses: Roche/Genentech, Takeda, Gilead Sciences, Janssen Ronan Le CallochConsulting or Advisory Role: TakedaTravel, Accommodations, Expenses: Janssen-Cilag Hervé TillyHonoraria: Bristol-Myers Squibb, Servier, RocheConsulting or Advisory Role: Karyopharm Therapeutics, Roche, JanssenTravel, Accommodations, Expenses: Roche Fabrice JardinHonoraria: Roche, CelgeneConsulting or Advisory Role: RocheTravel, Accommodations, Expenses: RocheNo other potential conflicts of interest were reported.
- Published
- 2021
- Full Text
- View/download PDF
30. Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
- Author
-
Vantyghem S, Peterlin P, Thépot S, Ménard A, Dubruille V, Debord C, Guillaume T, Garnier A, Le Bourgeois A, Wuilleme S, Godon C, Theisen O, Eveillard M, Delaunay J, Maisonneuve H, Morineau N, Villemagne B, Vigouroux S, Subiger F, Lestang E, Loirat M, Parcelier A, Godmer P, Mercier M, Trebouet A, Luque Paz D, Le Calloch R, Le Clech L, Bossard C, Moreau A, Ugo V, Hunault M, Moreau P, Le Gouill S, Chevallier P, Béné MC, and Le Bris Y
- Subjects
- High-Throughput Nucleotide Sequencing, Humans, Mutation, Prognosis, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes genetics, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders genetics, Neoplasms
- Abstract
Next-generation sequencing (NGS) is used to investigate the presence of somatic mutations. The utility of incorporating routine sequencing to guide diagnosis and therapeutic decisions remains unclear. We report the findings of an observational, multicenter study that aimed to assess the impact of somatic mutation testing by NGS in a reallife setting of chronic myeloid malignancies. A total of 177 patients were enrolled, partitioned into two overlapping groups. In group A (n=94), the indication was to search for clonal hematopoiesis, in a context of suspected myelodysplastic syndrome or myeloproliferative neoplasia. In group B (n=95), the theranostic impact of somatic mutations was studied. A panel of 34 genes was used on DNA extracted from blood or bone marrow samples. Within group A, the detection of clonal hematopoiesis supported the diagnosis of chronic myeloid malignancies for 31 patients while the absence of clonal hematopoiesis ruled out the suspected diagnosis in 47 patients. Within group B, NGS identified prognostically relevant somatic mutations in 32 patients, which had a therapeutic impact in 18 cases. By determining the presence or absence of somatic mutations, the application of NGS in daily practice was found to be useful for an integrated final diagnosis in 83% of the patients. Moreover, the search for somatic mutations had a prognostic impact that led to treatment modification in 19% of the cases. This study outlines the fact that adequate implementation of new investigations may have a significant positive medico-economic impact by enabling appropriate management of patients.
- Published
- 2021
- Full Text
- View/download PDF
31. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients.
- Author
-
Laribi K, Baugier de Materre A, Sobh M, Cerroni L, Valentini CG, Aoki T, Suzuki R, Takeuchi K, Frankel AE, Cota C, Ghez D, Le Calloch R, Pagano L, and Petrella T
- Subjects
- Acute Disease, Adult, Dendritic Cells, Humans, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute
- Abstract
The purpose of this study is to describe the clinical and prognostic features and to evaluate the outcome of different therapeutic approaches among patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who have been diagnosed and treated in different institutions. A total of 398 patients from 75 centers were included in the study. Treatment consisted of non-Hodgkin lymphoma (NHL)-like regimens in 129 (32.8%) patients and acute leukemia (AL)-like regimens in 113 (23.5%) patients. In 61 (15.5%) and 16 (4.1%) patients, chemotherapy was followed by allogeneic and autologous hematopoietic stem cell transplantation (HSCT), respectively. Twenty-seven (6.9%) patients received radiotherapy, 6 (1.5%) received new agents, and 62 (15.7%) received palliative care. After a median follow-up of 12 months, median overall survival (OS) was 18 months. Patients who received NHL/AL-like regimens, followed by allogeneic HSCT, had the best outcome; median OS was not reached. OS was 65 months for patients who underwent autologous HSCT; 18 months and 14 months, respectively, for those treated with AL-like and NHL-like regimens without consolidation; and 4 months for those receiving palliative care (P < .001). In BPDCN, chemotherapy with lymphoma- or AL-like regimens, followed by transplantation, represents the therapeutic strategy associated with the best outcome. Consolidation with allogeneic HSCT, when feasible, appears superior to autologous HSCT., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
32. Aplastic anemia related to thymoma: a survey on behalf of the French reference center of aplastic anemia and a review of the literature.
- Author
-
Gendron N, de Fontbrune FS, Guyard A, Fadlallah J, Chantepie S, D'Aveni M, Le Calloch R, Garnier A, Couturier MA, Morel V, Bernard C, Terriou L, Lazaro E, Socié G, and de Latour RP
- Subjects
- Humans, Surveys and Questionnaires, Anemia, Aplastic complications, Anemia, Aplastic diagnosis, Anemia, Aplastic epidemiology, Thymoma complications, Thymoma diagnosis, Thymoma epidemiology, Thymus Neoplasms complications, Thymus Neoplasms diagnosis, Thymus Neoplasms epidemiology
- Published
- 2020
- Full Text
- View/download PDF
33. Lymphomas with kidney involvement: the French multicenter retrospective LyKID study.
- Author
-
Kohn M, Karras A, Zaidan M, Bénière C, de Fréminville JB, Laribi K, Perrin MC, Malphettes M, Le Calloch R, Anglaret B, Martiniuc J, Bailly S, Chevret S, Molina T, Thervet E, and Thieblemont C
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols, France epidemiology, Humans, Kidney, Neoplasm Recurrence, Local, Retrospective Studies, Central Nervous System Neoplasms drug therapy, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse epidemiology
- Abstract
The LyKID study is a nationwide survey in France of lymphoma patients with renal involvement based on biopsy and/or imaging, to evaluate its impact on disease outcome and renal function. A total of 87 adult cases of B or T-cell lymphomas were retrospectively analyzed. Interstitial topography was observed in most of the kidney biopsies (54/66; 80%). Kidney failure (glomerular filtration rate <60 mL/min/1.73 m
2 ) was present in 47% of patients and was associated with non-significantly different outcome. After lymphoma treatment, 44% of patients had persistent chronic kidney failure (CKF); kidney failure at diagnosis was the only parameter associated with CKF in multivariate analysis. DLBCL (diffuse large B-cell lymphomas) represented half of the series, with noticeably CNS (central neurological system) relapse in 17% patients, while fewer than one of two patients had received CNS prophylaxis. To our knowledge, the LyKID study represents the largest published non-autopsy lymphoma series with renal involvement.- Published
- 2020
- Full Text
- View/download PDF
34. Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis.
- Author
-
Le Gall-Ianotto C, Le Calloch R, Couturier MA, Chauveau A, Lippert E, Carré JL, Misery L, and Ianotto JC
- Subjects
- Aged, Databases, Factual, Disease Progression, Female, Humans, Male, Middle Aged, Prognosis, Pruritus blood, Pruritus diagnosis, Risk Assessment, Risk Factors, Thrombocythemia, Essential blood, Thrombocythemia, Essential diagnosis, Thrombosis blood, Thrombosis diagnosis, Time Factors, Pruritus etiology, Thrombocythemia, Essential complications, Thrombosis etiology, Water adverse effects
- Abstract
Background: Thromboses and phenotypic evolutions (leukemia, myelofibrosis) are the most frequent complications in polycythemia vera (PV) and essential thrombocythemia (ET). Aquagenic pruritus (AP) is not only PV symptom, but is also present in ET. The presence of pruritus in PV is associated with a lower risk of arterial thrombosis., Aims: To date, no equivalent study has been done to analyse the impact of AP for ET patients., Materials & Methods: We used the data from our cohort of patients with myeloproliferative neoplasms seen in our institution (OBENE database, NCT02897297). We collect information at diagnosis, presence or not of AP and all types of complications during their follow-up. To avoid masked PV, all JAK2 positive cases were tested isotopic red mass cell if appropriate., Results: Among 396 ET patients, presence of AP was found in 42 (10.6%). ET patients with AP were more proliferative, more symptomatic at diagnosis and more difficult to treat. Furthermore, they presented increased risk of thromboses (30.9 versus 17%, P = .03; OR = 2.2 [1.01;4.66]) and phenotypic evolutions (33.3 versus 13.3%, P = .0007; OR = 3.2 [1.44;6.77]), during follow-up., Discussion: Aquagenic pruritus is classically associated to PV. But we confirmed here that AP is also present in ET and characterizes patients with higher risk of morbidity (thrombotic events and phenotypic evolutions)., Conclusions: The systematic determination of the presence of AP in ET patients should permit us to better identify these high-risk patients for better management and follow-up., (© 2019 International Society on Thrombosis and Haemostasis.)
- Published
- 2019
- Full Text
- View/download PDF
35. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
- Author
-
Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, and Leblond V
- Subjects
- Adult, Aged, Bendamustine Hydrochloride therapeutic use, Female, Humans, Lymphoproliferative Disorders drug therapy, Male, Middle Aged, Rituximab therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Waldenstrom Macroglobulinemia drug therapy
- Published
- 2019
- Full Text
- View/download PDF
36. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.
- Author
-
Mollard LM, Chauveau A, Boyer-Perrard F, Douet-Guilbert N, Houot R, Quintin-Roué I, Couturier MA, Dagorne A, Malou M, Le Calloch R, Luycx O, Thepot S, Hunault M, Guillerm G, Berthou C, Ugo V, Lippert É, and Ianotto JC
- Subjects
- Adult, Aged, Aged, 80 and over, Blast Crisis mortality, Cross-Sectional Studies, Female, Humans, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Palliative Care methods, Retrospective Studies, Survival Analysis, Survival Rate, Transplantation, Homologous, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Azacitidine therapeutic use, Blast Crisis therapy, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute therapy
- Abstract
Myeloproliferative neoplasms (MPN) are chronic disorders that can sometimes evolve into accelerated or leukemic phases. We retrospectively identified 122 patients with such blastic phases. The overall median survival was four months: 10.2 months for patients treated with intensive treatments compared to three months for best supportive care (p = .005). Azacytidine, intensive chemotherapies, or allogeneic stem cell transplantation gave the highest median survivals with 9, 10.2, and 19.4 months, respectively. Accelerated phases (AP) had a longer median survival compared to acute leukemia (4.8 months vs. 3.1 months; p = .02). In this retrospective and observational study, we observe that the longest survivals are seen in patients eligible for intensive treatments. Azacytidine shows interesting results in patients non-fit for intensive chemotherapy. Supportive care should probably be restricted to elderly patients and those with unfavorable karyotype. An early diagnosis of AP could also result in a better survival rate.
- Published
- 2018
- Full Text
- View/download PDF
37. Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review.
- Author
-
Babey H, Quéré G, Descourt R, Le Calloch R, Lanfranco L, Nousbaum JB, Cornec D, Tison A, and Chouaid C
- Subjects
- Animals, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal immunology, CTLA-4 Antigen immunology, Clinical Trials as Topic methods, Humans, Neoplasms immunology, Neoplasms pathology, Transplant Recipients, Antineoplastic Agents, Immunological therapeutic use, Immunocompromised Host immunology, Neoplasms drug therapy
- Abstract
Introduction: Because of their efficacy against numerous cancers, immune-checkpoint inhibitors (ICIs), anti-cytotoxic T-lymphocyte antigen-4, and anti-programmed cell death monoclonal antibodies are being used ever more often in oncology. However, some patients were excluded from clinical trials because of their comorbidities despite their potentially higher cancer frequencies, as is the case for immunocompromised patients. Areas covered: We analyzed reported preclinical and clinical information and evaluated the risk/benefit ratio for four immunocompromised populations: people living with human immunodeficiency virus (PLHs), solid-organ transplant recipients, recipients of hematopoietic stem-cell allografts, and patients with autoimmune diseases. Expert commentary: Information available in the literature is fragmentary and scarce, making it difficult to evaluate the risk/benefit ratio. It can, nonetheless, be noted that ICI use in PLHs seems possible. For solid-organ transplant recipients, the risk for the graft seems elevated. For the other two populations, it is difficult to conclude at this time.
- Published
- 2018
- Full Text
- View/download PDF
38. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
- Author
-
Le Clech L, Talarmin JP, Couturier MA, Ianotto JC, Nicol C, Le Calloch R, Dos Santos S, Hutin P, Tandé D, Cogulet V, Berthou C, and Guillerm G
- Subjects
- Adolescent, Adult, Aged, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents therapeutic use, Chemotherapy-Induced Febrile Neutropenia drug therapy, Chemotherapy-Induced Febrile Neutropenia epidemiology, Drug Therapy, Combination, Feasibility Studies, Febrile Neutropenia epidemiology, Febrile Neutropenia mortality, Female, Fever of Unknown Origin epidemiology, Fever of Unknown Origin mortality, Gram-Negative Bacterial Infections drug therapy, Gram-Negative Bacterial Infections epidemiology, Gram-Negative Bacterial Infections mortality, Humans, Male, Middle Aged, Practice Guidelines as Topic, Prospective Studies, Safety, Time Factors, Young Adult, Anti-Bacterial Agents administration & dosage, Febrile Neutropenia drug therapy, Fever of Unknown Origin drug therapy, Withholding Treatment
- Abstract
Introduction: Immediate empirical antibiotic therapy is mandatory in febrile chemotherapy-induced neutropenia, but its optimal duration is unclear, especially in patients with fever of unknown origin (FUO)., Objectives: The primary objective of this 20-month prospective observational study was to evaluate the feasibility and safety of short-term antibiotic treatment in afebrile or febrile patients exhibiting FUO, irrespective of their neutrophil count. The secondary objective was to describe the epidemiology of all episodes of febrile neutropenia., Methods: In the first phase of the study, empirical antibiotic therapy in FUO patients was stopped after 48 h of apyrexia, in accordance with European Conference on Infections in Leukaemia guidelines (n = 45). In the second phase of the study, antibiotics were stopped no later than day 5 for all FUO patients, regardless of body temperature or leukocyte count (n = 37)., Results: Two hundred and thirty-eight cases of febrile neutropenia in 123 patients were included. Neither the composite endpoint (p = .11), nor each component (in-hospital mortality (p = .80), intensive care unit admission (p = 0.48), relapse of infection ≤48 h after discontinuation of antibiotics (p = .82)) differed between the two FUO groups. Violation of protocol occurred in 17/82 episodes of FUO without any major impact on statistical results. Twenty-six (57.3%) and 22 (59.5%) FUO episodes did not relapse during hospital-stay (p = 1), and nine (20%) and five (13.5%) presented another FUO, respectively. One hundred and fifty-six episodes of febrile neutropenia (65.5%) were clinically or microbiologically documented, including 85 bacteremia., Conclusions: These results suggest that early discontinuation of empirical antibiotics in FUO is safe for afebrile neutropenic patients.
- Published
- 2018
- Full Text
- View/download PDF
39. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
- Author
-
Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, and Ysebaert L
- Subjects
- Adenine analogs & derivatives, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell microbiology, Male, Piperidines, Time Factors, Aspergillosis chemically induced, Aspergillosis epidemiology, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell epidemiology, Pyrazoles administration & dosage, Pyrazoles adverse effects, Pyrimidines administration & dosage, Pyrimidines adverse effects
- Abstract
Ibrutinib has revolutionized the management of chronic lymphocytic leukemia and is now being increasingly used. Although considered to be less immunosuppressive than conventional immunochemotherapy, the observation of a few cases of invasive fungal infections in patients treated with ibrutinib prompted us to conduct a retrospective survey. We identified 33 cases of invasive fungal infections in patients receiving ibrutinib alone or in combination. Invasive aspergillosis (IA) was overrepresented (27/33) and was associated with cerebral localizations in 40% of the cases. Remarkably, most cases of invasive fungal infections occurred with a median of 3 months after starting ibrutinib. In 18/33 cases, other conditions that could have contributed to decreased antifungal responses, such as corticosteroids, neutropenia, or combined immunochemotherapy, were present. These observations indicate that ibrutinib may be associated with early-onset invasive fungal infections, in particular IA with frequent cerebral involvement, and that patients on ibrutinib should be closely monitored in particular when other risk factors of fungal infections are present., (© 2018 by The American Society of Hematology.)
- Published
- 2018
- Full Text
- View/download PDF
40. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).
- Author
-
Le Calloch R, Lacut K, Le Gall-Ianotto C, Nowak E, Abiven M, Tempescul A, Dalbies F, Eveillard JR, Ugo V, Giraudier S, Guillerm G, Lippert E, Berthou C, and Ianotto JC
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents therapeutic use, Female, Fibrinolytic Agents therapeutic use, Humans, Male, Middle Aged, Polycythemia Vera complications, Risk Factors, Surveys and Questionnaires, Thrombocythemia, Essential complications, Medication Adherence statistics & numerical data, Polycythemia Vera drug therapy, Thrombocythemia, Essential drug therapy
- Abstract
The purpose of this study was to identify the incidence, causes and impact of non-adherence to oral and subcutaneous chronic treatments for patients with polycythemia vera or essential thrombocythemia. Patients receiving cytoreductive drugs for polycythemia vera or essential thrombocythemia were recruited at our institution ( Observatoire Brestois des Néoplasies Myéloprolifératives registry). They completed a one-shot questionnaire designed by investigators ( Etude de l'Observance Thérapeutique et des Effets Secondaires des Traitements study). Data about complications (thrombosis, transformation and death) at any time in the patient's life (before diagnosis, up until consultation and after the completion of the questionnaire) were collected. Sixty-five (22.7%) of 286 patients reported poor adherence (<90%) to their treatment with cytoreductive drugs and 46/255/18%) also declared non-adherence to antithrombotic drugs. In total, 85/286 patients (29.7%) declared they did not adhere to their treatment. Missing an intake was rare and was mostly due to forgetfulness especially during occupational travel and holidays. Patients who did not adhere to their treatment were characterized by younger age, living alone, having few medications but a high numbers of pills and determining their own schedule of drug intake. Having experienced thrombosis or hematologic evolution did not influence the adherence rate. Non-adherence to oral therapy was associated with a higher risk of phenotypic evolution (7.3 versus 1.8%, P =0.05). For patients treated for polycythemia vera or essential thrombocythemia, non-adherence to cytoreductive and/or antithrombotic therapies is frequent and is influenced by age, habitus and concomitant treatments, but not by disease history or treatment side effects. Phenotypic evolution seems to be more frequent in the non-adherent group., (Copyright© 2018 Ferrata Storti Foundation.)
- Published
- 2018
- Full Text
- View/download PDF
41. [An uncommon cause of subarachnoid hemorrhage].
- Author
-
Montelescaut E, Bailly P, Le Calloch R, Thill C, Aries P, and Ben Salem D
- Subjects
- Humans, Male, Middle Aged, Posterior Leukoencephalopathy Syndrome complications, Subarachnoid Hemorrhage etiology
- Published
- 2016
- Full Text
- View/download PDF
42. Fungal arthritis of the hip in patient with aplastic anaemia.
- Author
-
Le Calloch R, Ianotto JC, Guillerm G, and Tonnelier JM
- Subjects
- Humans, Male, Middle Aged, Anemia, Aplastic complications, Arthritis, Infectious etiology, Candidiasis etiology, Hip Joint
- Abstract
Aplastic anaemia is a rare and serious disease characterised by severe immunosuppression due to prolonged neutropenia and the use of immunosuppressants such as corticosteroids, cyclosporine and antithymocyte globulin. Candida species are pathogens of low virulence colonising the skin and the digestive tract of many healthy individuals. Nonetheless, the incidence of invasive candidal infection is increasing. The widespread use of central intravascular catheters, invasive procedures, broad-spectrum antibiotics and immunosuppresion predisposes patients to these infections. Eye, skin, cardiac, liver, spleen and brain infection are the most common sites of invasive candidiasis. Bone and joint infections are less frequent and Candida hip septic arthritis is extremely rare. We present here a patient treated for aplastic anaemia, who developed fungal arthritis of the hip and systemic candidaemia.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.